FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
Study finds unintended consequences of FDA initiative requiring manufacturers of unapproved drugs to obtain approval or remove them from the market but FDA says study does not consider broad impact of the initiative.
West-Ward could be the first to gain approval for phenylephrine in hypotension, but the drug’s widespread use as a stand-by medication during surgery could deter FDA enforcement against unapproved versions.